Navigation Links
Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
Date:6/22/2009

SAN MARINO, Calif., June 22 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article (accessible online as of June 16, 2009 in Molecular Therapy, the Official Journal of The American Society of Gene Therapy, www.nature.com/mt/) documents the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body, while sparing normal cells and healthy tissues and organs. Following the FDA's designation of Rexin-G as an Orphan Drug for the treatment of soft tissue sarcoma and osteosarcoma in 2008, the results of these two independent studies represent a major step toward gaining Accelerated Approval of Rexin-G for osteosarcoma in the United States.

"It took several years of painstaking safety studies, followed by gradual, progressive dose escalations, to the point where tumor control was consistently demonstrated, said Dr. Erlinda M. Gordon, Medical Director of Epeius Biotechnologies. Yet the progressive development strategy has finally paid off with real dividends: (1) By establishing the overall safety of the tumor-targeted gene delivery platform first and foremost, (2) By establishing critical pharmacological thresholds of bioactivity and dose-dependent efficacy for a new class of biological anti-cancer agents in otherwise intractable cancers, and (3) By validating the potential of Rexin-G to control metastatic cancer with single-agent efficacy, whereas other targeted therapies must be used in combination with one or more toxic agents in order to achieve even marginal results. The dividends for the cancer patient can now be measured in ter
'/>"/>

SOURCE Epeius Biotech
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Sparta Systems Unveils TrackWise(R) Clinical Quality Management Solution
2. China Pharma Holdings, Inc. Announces SFDA Approval for Rosuvastatin Clinical Trials
3. Perceptive Informatics Launches the Next Level of Integration in its Industry-Leading eClinical Suite
4. Transition Therapeutics Announces Appointment of Vice-President of Clinical Operations
5. CenterWatch to Introduce Key Findings from Surveys on Physician Referrals to Clinical Trials and Clinical Trial Volunteer Experiences at DIA Meeting
6. Microsoft to Showcase Clinical Trial Solutions From Discovery to Approvals at Drug Information Associations 2009 Annual Meeting
7. Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing in Humans
8. Digital Mammography and Clinical Review Display Units Energising the European Markets for Medical Imaging Display Monitors, Finds Frost & Sullivan
9. Bariatric Advantage High Protein Meal Replacement Clinical Study Presented at European Congress on Obesity
10. International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials
11. Ambulatory Surgery Centers Pivotal in Moving Outpatient Surgical Services Into Less Expensive, Clinically Appropriate Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... prom shopping reaching its final days, VogueQueen.com, a renowned ... its new and trendy apparels. Recently, the company has ... online shop. Additionally, it is now providing huge discounts ... to the company’s sales manager, the promotion will come ... He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 Doylestown ... covering a variety of men’s health questions. Paddock ... specific to men, why women live longer than men, ... Men's Health Made Simple featured on Doylestown ... get a hernia at any age. If you notice ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 A recent article ... provides a trio of suggestions for those seeking cosmetic ... days are rapidly approaching and the heat begins to enliven ... to their summer clothing, realizing that they didn’t work out ... , This can cause a sudden surge of people eager ...
(Date:7/12/2014)... July 12, 2014 Floor-grade ... of 4.1 out of 5. This above-average score ... been underpinning buyer negotiation power over the three ... Anna Son, “during the period, surging demand for ... associated with new product development, have placed upward ...
(Date:7/11/2014)... MagicQuinceaneraDresses.com, the popular online supplier of special occasion gowns, ... dresses . The company’s new items are specially designed ... a large amount of money. They are all available ... company’s online shop has become a one stop platform ... addition to exquisite Quinceanera dresses, it also offers great ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... sexual intercourse for couples lasts from 3 to 13 ... hours of sexual activity, according to a survey of ... Eric Corty and Jenay Guardiani conducted a survey of ... and Research, which include psychologists, physicians, social workers, marriage/family ...
... Will Arnett, Matthew Broderick, Steve Carell, Stephen, Colbert, ... James,Conan O,Brien, Rosie O,Donnell, Amy Poehler, Adam Sandler, Sarah ... Insult Comic Dog And Many More To Be Announced, ... today that,Kelsey Grammer, Ben Stiller, Grammy Award-winning band Maroon ...
... Work in primates points to possible weapon against human ... News) -- Researchers have successfully tested several Ebola vaccines ... first human vaccine for one of the world,s deadliest ... cannot be overlooked. We are seeing more and more ...
... French . , Montreal, March 31, 2008 ... novel gene responsible for a significant fraction of ALS (sporadic ... Lou Gehrigs disease, an incurable neuromuscular disorder that affects motor ... five years. , Published in the current online edition of ...
... March 31 The Epilepsy,Foundation,s quick reaction to a ... raises awareness of the need for Web security for ... and those who,use its online forums for help, support, ... posted rapidly flashing images to cause,serious injury and harm. ...
... --- University of Florida chemists are the first to use ... diseases -- without any previous knowledge of what these microscopic ... in the online edition of the Journal of Proteome Research, ... improved treatment of some types of cancer as well as ...
Cached Medicine News:Health News:Good sexual intercourse lasts minutes, not hours, therapists say 2Health News:Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRAL's(R) Live On-air Charity Special 'Night of Too Many Stars: An Overbooked Concert for Autism Education' Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET 2Health News:Researchers Successfully Test Ebola Vaccines 2Health News:Researchers identify a gene responsible for cases of Lou Gehrig's disease 2Health News:Epilepsy Foundation Takes Action Against Hackers 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 3
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Clinical Program Leverages Quark,s RNAi Technology, FREMONT, ... pharmaceutical company discovering and developing novel,RNA interference (RNAi)-based ... patient dosing in a Phase II trial,evaluating, ... (DME)., PF-4523655 is a novel siRNA drug ...
... Does Not Mean the End of Anti-Amyloid,Therapies -, ... studies,of potential new treatments for Alzheimer,s - even ... field,s knowledge and point scientists,toward advances in therapies ... the 2008 Alzheimer,s Association International Conference,on Alzheimer,s Disease ...
Cached Medicine Technology:Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 2Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 3Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 4Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 2Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 3Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 4Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 5Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 6Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 7Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 8Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 9Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 10Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 11